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Abstract
Purpose Nonmedical use of prescription opioid and stim-
ulants (NMUPO and NMUPS, respectively) has declined in
recent years, but remains an important public health
problem. Evidence regarding their relationships with
employment status remains unclear. We determined the
relationship between employment status and NMUPO and
NMUPS.
Methods We analyzed a cross-sectional, nationally repre-
sentative, weighted sample of 58,486 adults, ages 26 years
and older, using combined 2011–2013 data from the
National Survey on Drug Use and Health (NSDUH). We fit
two crude and two adjusted multivariable logistic regres-
sion models to assess the relationship between our two
different outcomes of interest: (1) past-year NMUPO and
(2) past-year NMUPS, and our exposure of interest:
employment status, categorized as (1) full time, (2) part
time, (3) unemployed, and (4) not in the workforce. Our
adjusted models featured the following covariates: sex,
race, age, marital status, and psychological distress, and
other nonmedical use.
Results Prevalence of NMUPO was higher than NMUPS
(3.48 vs. 0.72%). Unemployed participants had the highest
odds of NMUPO [aOR 1.45, 95% CI (1.15–1.82)], while
those not in the workforce had the highest odds of NMUPS
[aOR 1.71, 95% CI (1.22–2.37)]. Additionally, part-time
and unemployed individuals had increased odds of
NMUPS [aORs, 95% CI 1.59 (1.09–2.31) and 1.67
(1.11–2.37) respectively], while those not in the workforce
had decreased odds of NMUPO [aOR 0.82, 95% CI
(0.68–0.99)] relative to full-time participants.
Conclusions There is a need for adult prevention and
deterrence programs that target nonmedical prescription
drug use, especially among those unemployed or not in the
workforce.
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ADHD Attention-deficit hyperactivity disorder
NMPD Nonmedical prescription drug(s)
NMUPO Nonmedical prescription opioid use
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NSDUH National Survey on Drug Use and Health
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US United States
Introduction
Nonmedical prescription drug (NMPD) use, particularly
nonmedical use of prescription opioids (NMUPO), has
declined in recent years, yet is still an important public
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health problem in the US [1]. Recent literature cites an
overall trend in increasing deaths from prescription drugs
and heroin [2, 3], but decreasing deaths from all other illicit
drug use [4–7]. Nonmedical prescription drug use has a
profound impact on economic productivity, criminal justice
costs, drug use disorder treatment, and medical complica-
tions [8]. Further, unintended consequences like the recent
increase in heroin use may be attributed partially to
NMUPO [9]. In 2006, NMUPO alone cost the United
States (US) about $42 billion in lost productivity, $8.2
billion in criminal justice costs, and $1 billion in medical
complications [8].
In general, NMPD use has been mostly examined among
youth and young adult populations. For example, longitu-
dinal data of high school seniors show that while most
NMUPO was transient, approximately one-third of users
continued use past the age of 18 years and were conse-
quently at higher odds of developing substance use
behaviors, especially recent binge drinking and past-year
marijuana and other NMPD use [10]. In a different cross-
sectional studies, Martins and colleagues found that com-
pared to young adults (18–22 years old) enrolled in col-
lege, 18- to 22-year-old people not enrolled were
significantly more likely to endorse NMUPO and less
likely to endorse nonmedical prescription stimulants
(NMUPS) [11]. Relevant to Martins’ findings is research
showing that earlier entries into adult roles (e.g., foregoing
university enrollment to enter the workforce) may be
detrimental to individuals who are not well prepared for
them [12]. However, some evidence demonstrates that
employment is associated with decreased misuse of pre-
scription drugs, as is the case among government
employees and those whose employers had a drug-free
workplace policy [13].
While this previous research is useful in understanding
trends of NMPD use, the lens is on early initiation, which is
less helpful for identifying characteristics in adult popula-
tions. For instance, while many factors may explain the rise
in NMUPO among those not enrolled in college, it is
unclear how this translates to employment status. Miller
and colleagues observed that employment is protective for
NMUPO for those 18–25 years old, but there remains the
question of attribution of co-occurring adult roles on sub-
stance use decreases past that age period [13]. Smith and
Farah reveal that research exploring employment’s rela-
tionship with NUMPS has been scarce among young adult
and older working populations [14]. For instance, pre-
scription stimulants, which are commonly used to control
childhood (attention-deficit hyperactivity disorder) ADHD
and narcolepsy, are increasingly used in adulthood to
control persistent symptoms from childhood [15], which
are associated with difficulty in obtaining and keeping full-
time employment. On the other hand, NMUPS has also
been on the rise among employed adults, mainly due to
desires to improve performance, increase productivity,
remain competitive with one’s peers [16, 17], or for
memory improvement among older adults.
While the deleterious consequences of NMPD use
have been researched extensively, less focus has been
paid to identifying social characteristics that influence
and are influenced by NMPD use. We view the most
powerful intervening forces associated with both the
labor market and NMPD use to be federal and state
regulations, some of which may mandate specific clinical
practices. By examining the associations between NMPD
use and employment, we can identify groups in which
NMPD use is overrepresented and, consequently, rec-
ommend regulatory and clinical interventions that would
improve users’ lives. Thus, the goals of this study were
to explore how NMUPO and NMUPS vary by employ-
ment status among US adults. We aimed to compare the
prevalence and odds of past-year NMUPO and NMUPS
among full-time workers with part-time employed,
unemployed, and those not in the workforce, adjusting
for age, sex, race, past-year psychological distress,
marital status, and the NMPD use not being modeled
(i.e., adjusting for NMUPO in the case we were mod-
eling NMUPS and vice versa).
Materials and methods
Study sample and measures
We analyzed data from 58,486 adults ages 26 years and
older from the 2011 (n = 58,397), 2012 (n = 55,268), and
2013 (n = 55,160) NSDUH public use files. Three con-
secutive NSDUH years were combined to increase the
sample size, as prevalence estimates of NMUPO and
NMUPS are low. Respondents are not sampled twice. The
NSDUH is an annual cross-sectional survey sponsored by
the Substance Abuse and Mental Health Administration
[18] and is designed to provide estimates of the prevalence
of drug use and disorders in the household population of
the US among those 12 years and older. All respondents
provided information about their drug experiences and
socio-demographic characteristics. The NSDUH question-
naire instrument has sensitivity values ranging from 0.8 to
0.97 for most substances, and specificity values ranging
from 0.7 to 0.95 [19].
Outcome variables
Outcomes of interest: (1) past-year nonmedical prescrip-
tion opioid use and (2) past-year nonmedical prescription
stimulant use.
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Nonmedical use of prescription opioids
and prescription stimulants
NMUPO was defined as any self-reported use of pre-
scription pain relievers that were not prescribed for the
respondent or that the respondent took only for the
experience or feeling they caused [20]. All respondents
were given the following instructions: ‘‘These questions
are about prescription pain reliever use. We are not
interested in your use of over-the-counter pain relievers
that can be bought in stores without a doctor’s pre-
scription.’’ The NSDUH used a similar screening ques-
tion that assessed whether the respondent had ever used
a core prescription stimulant that was not prescribed or
taken for the experience or feeling it caused [18]. Past-
year NMUPO and NMUPS were recorded based on
responses to questions asking how much time had passed
since last NMUPO and NMUPS, respectively. These
groups are not mutually exclusive, thus an individual
could self-report both past-year NMUPO and past-year
NMUPS.
Primary exposure variable
Current employment status is classified in the NSDUH as:
(1) employed full time (at least 35 h per week), (2)
employed part time (less than 35 h per week), (3) unem-
ployed (no job or layoff, but looking for work), and (4) not
in the workforce. Individuals ‘‘not in the workforce’’ are
not actively seeking work, which includes retirees, disabled
persons, homemakers, students, and those who have given
up on attaining employment.
Demographic covariates
Demographic variables selected for this study included sex,
age, race (non-hispanic white, combined non-white races),
and marital status. Some of these covariates, which are
proxies for social maturity (i.e., advanced age and mar-
riage), in addition to white race, male sex [13], and psy-
chological distress, may affect the strength of the
relationship between the outcomes and employment status.
Due to small sample sizes and similar use patterns within
racial/ethnic groups, plus the appreciably higher prevalence
and frequency of prescription drug use within the white
racial group [11], we chose to combine non-white races
into a single category. We chose not to include education in
our analysis due to sample size constraints and the presence
of our main exposure variable, employment, a variable
strongly predicted by education. Additionally, marital sta-
tus was dichotomized due to similar use patterns among
non-married subgroups, including divorced, separated, and
widowed respondents.
This study only included adults aged 26 years and older
because of our focus on the adult workforce; therefore we
excluded young adults who were still completing their
studies. Restricting our population to this age group sheds
light on a previously understudied relationship between
employment status and nonmedical prescription drug-using
populations over 25 years [21].
Past-year psychological distress
We also adjusted for the presence of psychological distress,
since several studies have shown its association with
NMUPO [22, 23]. Weyandt and colleagues list the body of
literature demonstrating the association between NMUPS
and depression, anxiety, stress, and internal restlessness
[24]. Serious psychological distress was measured using
the Kessler 6 (K6) screening instrument for non-specific
psychological distress. The tool consists of six items, each
with a 0-to-4-point rating scale that screens for general
distress in the past year (Cronbach’s a = 0.89).
Other use
We controlled for the effect of NMUPS on the association
between employment status and NMUPO. Similarly, we
controlled for the effect of NMUPO on the association
between employment status and NMUPS.
Statistical analyses
Data were weighted to reflect the complex design of the
NSDUH sample and were analyzed using SAS 9.4 (SAS
Institute, Cary, NC, USA). We used Taylor series estima-
tion methods to obtain proper standard error estimates for
the Chi-square cross-tabulations and logistic regressions.
All percentages reported are weighted by study weights.
Logistic regressions estimated the log odds of NMUPO and
NMUPS. All adjusted log odds of NMUPO and NMUPS
were controlled for sex, age, race, and marital status, past-
year psychological distress, and past-year use of the drug
that was not modeled.
Results
Prevalence of past-year NMUPO and NMUPS
by employment status (Table 1)
Past-year prevalence of NMUPO and NMUPS were 3.48
and 0.72%, respectively. Among those unemployed, 6.91
and 1.70% were NMUPO and NMUPS, respectively, the
highest prevalences within any employment status. Among
those employed full time, 3.84% were NMUPO and 0.64%
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were NMUPS. Among those employed part time, 3.77%
were NMUPO and 1% were NMUPS. Lastly, among those
not in the workforce, 2.34% were NMUPO and 0.62%
were NMUPS (Table 1). A large plurality of those not in
the workforce were those over 65 years old.
Adjusted odds of NMUPO and NMUPS
by employment status (Table 2)
The adjusted odds of each outcome by employment status
varied significantly. Unemployed respondents had
increased odds of NMUPO [aOR 1.45, 95% CI
(1.15–1.82)] and of NMUPS [aOR 1.67, 95% CI
(1.11–2.51)] compared to those employed full time. Indi-
viduals not in the workforce [aOR 1.71, 95% CI
(1.22–2.37)] and part-time employees [aOR 1.59, 95% CI
(1.09–2.31)] were more likely to endorse past-year
NMUPS than their full-time counterparts. Individuals not
in the workforce were 18% less likely to endorse NMUPO
[aOR 0.82, 95% CI (0.68–0.99)].
Adjusted odds of NMUPO and NMUPS
by demographics, and social and behavioral
attributes (Table 2)
Adjusting for all covariates, males were 1.35 times more
likely to endorse NMUPO than females [aOR 1.35, 95% CI
(1.14–1.59)], while the odds ratio of NMUPS by sex was
not significant. Non-whites were less likely to endorse
NMUPO [aOR 0.80, 95% CI (0.69–0.92)] and NMUPS
[aOR 0.54, 95% CI (0.39–0.75)] than non-hispanic whites.
Individuals aged 35–49 years were less likely than those
aged 26–34 years to endorse NMUPO [aOR 0.65, 95% CI
(0.57–0.74)] and NMUPS [aOR 0.46, 95% CI (0.35–0.59)],
Table 1 Past-year prevalence
of nonmedical prescription
opioid and stimulant use among
adults aged 26 years and older;
data from National Survey on
Drug Use and Health (NSDUH),
2011–2013
Socio-demographic characteristics Overall NMUPS NMUPO
Na %b Na %b v2 p value Na %b v2 p value
Overall 58486 512 0.72 2485 3.48
Employment \0.0001* \0.0001*
Full time 32512 51.99 257 0.64 1398 3.84
Part time 7320 11.75 74 0.99 317 3.77
Unemployed 3067 4.35 60 1.70 247 6.91
Other 15587 31.90 121 0.62 523 2.34
Age (years) \0.0001* \0.0001*
26–34 16564 18.4 308 2.11 1203 7.42
35–49 22521 30.42 156 0.68 944 4.12
50? 19401 51.18 48 0.25 338 1.70
Sex 0.19 0.0004*
Female 31786 52.22 257 0.66 1180 3.06
Male 26700 47.78 255 0.79 1305 3.95
Racec 0.0055* 0.3229
White 38645 67.96 380 0.81 1719 3.55
Non-white combined 19841 32.04 132 0.53 766 3.35
Psychological distress \0.0001* \0.0001*
No 52046 90.63 331 0.52 1770 2.81
Yes 6440 9.37 181 2.63 715 10.05
Marital statusd \0.0001* \0.0001*
Unmarried 25358 40.14 365 1.25 1506 4.86
Married 33128 59.86 147 0.36 979 2.57
* p value\0.05
a Frequencies are unweighted and proportions are weighted
b Proportions listed are conditional probabilities of each outcome given the socio-demographic
characteristic
c Due to high prevalence of prescription drug use among white participants and low prevalence among
black, Hispanic, Asian, and other races, race was dichotomized into white and non-white
d Divorced, widowed, and separated individuals were included in this category since no significant dif-
ferences were observable between these subgroups
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while those ages 50 years and older were between three
and six times less likely to endorse NMUPO [aOR 0.30,
95% CI (0.25–0.36)] and NMUPS [aOR 0.17, 95% CI
(0.12–0.25)] than those aged 26–34 years. Married
respondents were less likely than unmarried respondents to
endorse NMUPO [aOR 0.66, 95% CI (0.58–0.75)] and
NMUPS [aOR 0.45, 95% CI (0.34–0.60)], and those
endorsing past-year psychological distress were about three
times more likely to endorse NMUPO [aOR 2.94, 95% CI
(2.55–3.39)] and slightly less likely to endorse NMUPS
[aOR 2.24, 95% CI (1.66–3.03)] than those without psy-
chological distress.
Adjusted odds of other use (Table 2)
Not controlling for other use would have overestimated the
associations between employment status and NMUPO/
NMUPS. After controlling for other use, we observed that
those endorsing past-year NMUPO were ten times more
likely to endorse NMUPS [aOR 9.77, 95% CI
(7.49–12.73)] than those without NMUPO. Similarly, those
endorsing past-year NMUPS were also ten times more
likely to endorse NMUPO [aOR 10.16, 95% CI
(7.91–13.04)] than those without NMUPS.
Discussion
Our analysis indicated higher odds of NMUPO among the
unemployed and 18 % lower odds of NMUPO among
those not in the labor force, compared with those who were
employed full time. The data also showed higher odds of
NMUPS among all non-full-time employed groups com-
pared with those employed full time, despite the fact that
drug use and drug use disorder are highly prevalent among
full-time employed people [25]. Our findings on these
associations parallel other research on engaging in adult
roles, such as marriage and parenthood [26].
Additionally, our findings on the inverse relationship
between increasing age range among adults aged 26 years
and older (i.e., from 26–34 to 35–49 to 50?) and the
decreasing odds of NMUPO and NMUPS confirm the
results from the Monitoring the Future study [27]. While it
has been shown that those who use illegal and prescription
drugs may decrease their usage with the onset of other
adult roles (i.e., marriage, parenthood, full-time employ-
ment, etc.) [28], drug misuse remains common in adults
under 50 years, and nonmedical use prevention strategies
tailored to particular age groups must be considered. For
instance, though abuse risks are lower in older chronic pain
patients [29], clinicians have adopted a Universal Precau-
tions approach to pain management whereby patients are
assessed for risk factors related to problematic use of pain
medication [29]. Our finding that not being in the labor
force (e.g., retired) is protective of NMUPO could mean
that clinical precautions are working. We observed a pos-
itive association between those not in the labor force and
NMUPS. This could be partially attributable to those not in
the labor force (e.g., retired) irresponsibly using cognitive
enhancers to improve memory [30]. Similar actions (i.e.,
Table 2 Crude and adjusted odds of past-year nonmedical prescrip-
tion opioid and stimulant use among adults aged 26 years and older;
data from the National Survey on Drug Use and Health (NSDUH),
2011–2013
Unadjusted model NMUPS NMUPO
OR 95% CI OR 95% CI
Employment status
Full time – – – –
Part time 1.56* 1.07–2.26 0.98 0.81–1.19
Unemployment 2.70* 1.84–3.95 1.86* 1.51–2.29
Other 0.98 0.73–1.31 0.60* 0.50–0.72
Adjusted model aOR 95% CI aOR 95% CI
Employment status
Full time – – – –
Part time 1.59* 1.09–2.31 1.02 0.84–1.24
Unemployment 1.67* 1.11–2.51 1.45* 1.15–1.82
Other 1.71* 1.22–2.37 0.82* 0.68–0.99
Age (years)
26–34 – – – –
35–49 0.46* 0.35–0.59 0.65* 0.57–0.74
50? 0.17* 0.12–0.25 0.30* 0.25–0.36
Sex
Female – – – –
Male 1.22 0.90–1.69 1.35* 1.14–1.59
Raceb
White – – – –
Non-white combined 0.54* 0.39–0.75 0.80* 0.69–0.92
Psychological distress
No – – – –
Yes 2.24* 1.66–3.03 2.94* 2.55–3.39
Marital statusc
Unmarried – – – –
Married 0.45* 0.34–0.60 0.66* 0.58–0.75
Past-year use of
NMUPO
9.77* 7.49–12.73 – –
Past-year use of NMUPS – – 10.16* 7.91–13.04
* p value\0.05
a Due to high prevalence of prescription drug use among white
participants and low prevalence among black, Hispanic, Asian, and
other races, race was dichotomized into white and non-white
b Divorced, widowed, and separated individuals were included in this
category since no significant differences were observable between
these subgroups
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clinical and regulatory) may be in order to educate stim-
ulant users to prevent stimulant diversion among those not
in the labor force.
Unemployed NSDUH respondents had higher odds of
both NMUPO and NMUPS than their full-time counter-
parts. Unemployment and its correlates are associated with
health issues from cardiovascular disease to mental disor-
ders. A Danish study showed that men on unemployment
benefits were 1.50, 1.28, and 2.00 times more likely to have
diabetes, cancer, and mental disorders, respectively, than
employed men. Other social benefit statuses, means-tested
cash-benefit and disability pensions (both may be consid-
ered unemployed statuses in the US), were associated with
a much higher disease incidence [31]. Another study
demonstrated that unemployment was associated with
completed suicides, a figure that inflates among those with
financial problems [32]. The observation that unemploy-
ment is associated with a host of diseases, particularly
mental disorders (which we also found), is a strong caution
for those instituting policies regulating NMPD control.
Physicians should be aware of patients’ employment status
and the elevated risk between unemployment and non-
medical drug use and drug and mental disorders prior to
prescribing. Aside from prescription drug monitoring pro-
grams (PDMPs), which assist prescribers, an increased
layer of precaution should include a physician requirement
to assess abuse potential, specifically of unemployed
patients.
We lastly found that part-time employment and psy-
chological morbidity are positively associated with
NMUPO. Studies show that people struggling with psy-
chological distress and concurrent NMPD use are less
likely to attain and maintain full-time employment, which
may leave them in part-time or temporary employment
(i.e., precarious employment) [33, 34].
The associations between employment status, NMUPO,
and NMUPS yield important public health implications. By
improving our understanding of these associations and the
role of employment in drug use behaviors and modes of
access, drug prevention and deterrence programs can target
users more effectively, especially when combined with
regulation. It is imperative that interventions are sensitive
to non-full-time employed people, a population that our
data suggests is one with greater social disadvantage. Non-
full-time employed people may suffer disproportionately
from the indirect harms of NMUPO and NMUPS insomuch
that they have less income, less wealth, and perhaps, less
dynamic social support structures [35, 36], such as family-,
neighborhood-, and community-level social ties that would
help mitigate harms related to misuse. While this popula-
tion would clearly benefit from targeted prevention and
deterrence, policy measures like withholding social bene-
fits due to a positive drug screen [37] should be highly
discouraged. Substance use disorders are increasingly rec-
ognized as a public health issue and not one of criminal
justice, and withholding social support (including treat-
ment) from those with the highest need will contribute to
increasing social inequalities.
This study is not without limitations. The cross-sectional
design limits inferences, as temporality is impossible to
establish. For instance, the question of whether unem-
ployment causes NMUPO and NMUPS or vice versa
remains unknown. To demonstrate any changes over time
in nonmedical prescription drug use patterns, longitudinal
data would be required. However, this study does provide
valuable information on the prevalence of NMUPS an
NMUPO across different groups of adults of working age
in a nationally representative sample. These data are useful
in describing how use varies across a broad social structure
of our society. While the downstream social and economic
costs of nonmedical prescription drug use are very appar-
ent, the drivers of initiation in adult working populations
are less than finite. The research presented in this paper
informs us that regulatory and clinician-initiated preven-
tion strategies should be tailored for the myriad of drug
classes, employment groups, and other social strata, such as
age groups.
Conclusion
The current research, in conjunction with the context of
today’s nonmedical prescription drug use epidemic, leads
us to comment on two actions the public health community
can take, which are separate from the regulatory and
clinical suggestions described earlier. Firstly, the findings
from the current study highlight the need to examine in
greater detail the determinants of NMUPO and NMUPS
among the part-time employed and those not in the work-
force. These unique associations indicate that analyses of
prescription substance use among adults should not broadly
categorize employment status or prescription drugs, since
significant patterns across demographic, social, and
behavioral subgroups exist. Secondly, as is already being
done in some communities, public health practitioners must
target patient advocacy partners to address the push of
stronger, more addictive medications into doctors’ offices
and patients’ hands. A number of studies [38, 39] describe
prescription opioid-related harms as being associated with
highly potent oxycodone formulations, for which accessi-
bility of market entry has been quick and aggressive.
Reproaching legislative flexibility that allows pharmaceu-
tical companies to push unnecessarily potent formulations
into populations with little added medical benefit than
relatively less potent formulations should be prioritized.
The findings presented in the current study elucidate the
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association between employment status and NMPD, which
should guide translational epidemiologists to study effec-
tive regulatory leverage points to control employment and
prescription drugs to limit the problem’s growth.
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